Search
Tetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalThe only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks selective potassium channels.
Categories: MATE 1 Substrates, MATE 2 SubstratesSerotonin
go.drugbank.com/drugs/DB08839InvestigationalNutraceuticalFor temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.
Categories: Heterocyclic Compounds, 2-RingSynonyms: 3-(2-Aminoethyl)-1H-indol-5-ol, 5-HTEllagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement … of cardiovascular function in adolescents who are obese (phase 2 trial), and topical treatment of solar lentigines.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Heterocyclic Compounds, 1-RingUlipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalA recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily … It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ESMYA® 5 MG COMPRIMIDOS, เอสมายาชนิดเม็ด 5 มก.Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: DROPTON®, GENBIEMOD®Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MGMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADATofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: XELJANZ®5MG, เซลแจนซ์ (ยาเม็ด 5 มก.)Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTAS